Results 191 to 200 of about 1,011,898 (268)

Editorial: Patient education in the treatment of chronic pain. [PDF]

open access: yesFront Pain Res (Lausanne)
Modarresi S, Shafiee E.
europepmc   +1 more source

A Proof‐of‐Concept Assessment of a Novel Wearable Eyelid Muscle Device: A Pre‐Clinical Animal Cadaver Study for Eyelid Closure Restoration

open access: yesAdvanced Robotics Research, EarlyView.
This article introduces a soft wearable eyelid sling device incorporating a hydraulic soft artificial muscle (SAM) for achieving complete closure of an eyelid. The SAM is driven by a cam mechanism that provides a displacement profile closely matched with those of a healthy eyelid.
Patrick Pruscino   +7 more
wiley   +1 more source

Pain Retrained: Outcomes Analysis of an Online, Interdisciplinary Chronic Pain Education Programme. [PDF]

open access: yesEur J Pain
McCarron M   +6 more
europepmc   +1 more source

Piezo2 Mediates a Vicious Cycle of “Mechanical Homeostasis Imbalance—Inflammation” in Sensory Nerves and the Cartilage Endplate

open access: yesAdvanced Science, EarlyView.
In a lumbar spine instability model, dorsal root ganglion cells mediate the perception of relevant mechanical stresses through Piezo2 and subsequently release CGRP. CGRP activates the NF‐κB signaling pathway in cartilage endplate cells through the receptor RAMP1.
Hanpeng Xu   +16 more
wiley   +1 more source

Mesenchymal Stromal Cell‐Mediated Intercellular Communication: Mapping the Interactome for Skeletal Muscle Homeostasis and Regeneration

open access: yesAdvanced Science, EarlyView.
Liu et al. define a systems‐level interactome of fibroadipogenic progenitor (FAP)‐mediated signaling in skeletal muscle by integrating single‐cell transcriptomics with FAP depletion‐based perturbation analysis. Functional interrogation using a conditioned media bioassay links predicted signaling to multicellular outcomes, establishing a framework to ...
Xingyu Liu   +13 more
wiley   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy